138 related articles for article (PubMed ID: 36233811)
1. Survival Analysis in Patients with Lung Cancer and Subsequent Primary Cancer: A Nationwide Cancer Registry Study.
Chou WR; Shia BC; Huang YC; Ho CW; Chen M
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233811
[TBL] [Abstract][Full Text] [Related]
2. Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis.
Liu YY; Chen YM; Yen SH; Tsai CM; Perng RP
Lung Cancer; 2002 Feb; 35(2):189-94. PubMed ID: 11804692
[TBL] [Abstract][Full Text] [Related]
3. Multiple primary malignancies involving lung cancer: a single-center experience.
Ventura L; Carbognani P; Gnetti L; Rossi M; Tiseo M; Silini EM; Sverzellati N; Silva M; Succi M; Braggio C; Cattadori S; Bocchialini G; Balestra V; Rusca M; Ampollini L
Tumori; 2021 Jun; 107(3):196-203. PubMed ID: 32578517
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer.
Wang H; Hou J; Zhang G; Zhang M; Li P; Yan X; Ma Z
Cancer Gene Ther; 2019 Nov; 26(11-12):419-426. PubMed ID: 30700800
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status.
Hsu CH; Tseng CH; Chiang CJ; Hsu KH; Tseng JS; Chen KC; Wang CL; Chen CY; Yen SH; Chiu CH; Huang MS; Yu CJ; Tsai YH; Chen JS; Tsai CM; Chou TY; Lin KC; Tsai MH; Lee WC; Ku HY; Liu TW; Yang TY; Chang GC
Oncotarget; 2016 Jul; 7(29):46628-46635. PubMed ID: 27191886
[TBL] [Abstract][Full Text] [Related]
6. Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers.
Chou WR; Shia BC; Huang YC; Ho CW; Chen M
J Clin Med; 2022 Sep; 11(17):. PubMed ID: 36079152
[TBL] [Abstract][Full Text] [Related]
7. Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan.
Chen PC; Lee YC; Su YC; Lee CH; Chen JH; Chen CY
PLoS One; 2022; 17(4):e0266960. PubMed ID: 35446891
[TBL] [Abstract][Full Text] [Related]
8. EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan.
Chung CH
Oncol Lett; 2019 Dec; 18(6):6090-6100. PubMed ID: 31788083
[TBL] [Abstract][Full Text] [Related]
9. Postoperative Management of Multiple Primary Cancers Associated with Non-small Cell Lung Cancer.
Shoji F; Yamazaki K; Miura N; Katsura M; Oku Y; Takeo S; Maehara Y
Anticancer Res; 2018 Jun; 38(6):3773-3778. PubMed ID: 29848742
[TBL] [Abstract][Full Text] [Related]
10. Prognosis associated with synchronous or metachronous multiple primary malignancies in patients with completely resected non-small cell lung cancer.
Komatsu H; Izumi N; Tsukioka T; Inoue H; Hara K; Miyamoto H; Nishiyama N
Surg Today; 2019 Apr; 49(4):343-349. PubMed ID: 30417262
[TBL] [Abstract][Full Text] [Related]
11. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer.
Kwon BS; Park JH; Kim S; Park S; Ji W; Kim WS; Lee JC; Park YR; Choi CM
Tumori; 2019 Jun; 105(3):216-224. PubMed ID: 30905312
[TBL] [Abstract][Full Text] [Related]
13. Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort.
Liang SK; Keng LT; Chang CH; Wen YF; Lee MR; Yang CY; Wang JY; Ko JC; Shih JY; Yu CJ
Front Oncol; 2020; 10():590356. PubMed ID: 33489886
[TBL] [Abstract][Full Text] [Related]
14. Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation.
Chen PY; Wang CC; Hsu CN; Chen CY
Front Pharmacol; 2021; 12():720687. PubMed ID: 34434112
[No Abstract] [Full Text] [Related]
15. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
[TBL] [Abstract][Full Text] [Related]
16. The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.
Huang YH; Hsu KH; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
Target Oncol; 2022 May; 17(3):295-306. PubMed ID: 35460474
[TBL] [Abstract][Full Text] [Related]
17. High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer.
Zeng T; Xu H; Liu Y; Sun C; Yang F; Liang Y; Huang X; Fu Z; Li W; Yin Y
Front Oncol; 2022; 12():985734. PubMed ID: 36313724
[TBL] [Abstract][Full Text] [Related]
18. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
Lee JH; Chen HY; Hsu FM; Chen JS; Liao WY; Shih JY; Yu CJ; Chen KY; Tsai TH; Yang JC
Oncologist; 2019 Dec; 24(12):e1417-e1425. PubMed ID: 31127020
[TBL] [Abstract][Full Text] [Related]
19. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
